• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2012 Product Image

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2012

  • ID: 2366412
  • December 2012
  • 83 pages
  • Global Markets Direct

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 6
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) 9
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics under Development by Companies 11
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics under Investigation by Universities/Institutes 13
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics – Products under Development by Companies 19
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics Development 22
Pfizer Inc. 22
Dendreon Corporation 23
Debiopharm Group 24
Cadila Pharmaceuticals Ltd. 25
Altor BioScience Corporation 26
TRACON Pharmaceuticals, Inc. 27
Pierre Fabre Medicament 28
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Mycobacterium w - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
5-Fluoro-2-Deoxycytidine + Tetrahydrouridine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
erlotinib hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
vorinostat - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Javlor + Gemcitabine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
gefitinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Cisplatin + Methotrexate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TRC-105 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PF-03446962 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
sunitinib malate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
sunitinib malate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Gemcitabine + Oxaliplatin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Gemcitabine + Cisplatin + Lenalidomide - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 54
Methotrexate + Vinblastine + Cisplatin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Panitumumab + Radiotherapy - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Bevacizumab + Cisplatin + Gemcitabine + Paclitaxel - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Gemcitabine + Paclitaxel + Doxorubicin + Pegfilgrastim - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ALT-801 + Gemcitabine + Cisplatin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
paclitaxel - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Gemcitabine + Cisplatin + Lenalidomide - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DN-2402 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Debio-1141 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Gemcitabine + Cisplatin + Panitumumab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Pazopanib + Vinflunine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Pemetrexed + Cisplatin + Dexamethasone + Vitamins - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
cabazitaxel - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
valrubicin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Gemcitabine + Paclitaxel - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Cisplatin + Gemcitabine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics – Drug Profile Updates 76
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics – Discontinued Products 79
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics - Dormant Products 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables
Number of Products Under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H2 2012 9
Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
Pfizer Inc., H2 2012 22
Dendreon Corporation, H2 2012 23
Debiopharm Group, H2 2012 24
Cadila Pharmaceuticals Ltd., H2 2012 25
Altor BioScience Corporation, H2 2012 26
TRACON Pharmaceuticals, Inc., H2 2012 27
Pierre Fabre Medicament, H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 34
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics – Drug Profile Updates 76
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics – Discontinued Products 79
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics – Dormant Products 80
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics – Dormant Products (Contd..1) 81

List of Figures
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H2 2012 9
Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Route of Administration, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Molecule Type, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 34

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos